Sign in

CIK 0001649989

  • Non-accelerated filer
  • Smaller reporting company

Outlook Therapeutics, Inc.

Sign in to watch
Ticker
OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Sep 30
Incorporated
DE
Entity type
Operating
EIN
383982704
Phone
+1 609-619-3990
Business address
111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
Former names
Oncobiologics, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 3 Insider Initial Statement of Ownership
  6. 4 Open-market buy Director bought 10,000 shares at $1.82 ($18,200)
  7. 4 Open-market buy Director bought 10,000 shares at $1.82 ($18,200)
  8. 4 Open-market buy CEO, Pres, CFO, Treas & Secy bought 10,000 shares at $1.83 ($18,300)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Open-market sale Chief Commercial Officer sold 8,554 shares at $2.09 ($17,861)
  17. 4 Open-market sale Chief Operating Officer sold 15,900 shares at $2.09 ($33,199)
  18. 4 Open-market sale Chief Commercial Officer sold 56,973 shares at $2.55 ($145,281)
  19. 4 Open-market sale Chief Operating Officer sold 63,700 shares at $2.55 ($162,435)
  20. 4 Grant or award Director acquired 1,013,627 shares (grant or award)

Page 7 of 16 · 305 filings